Single Center Experience Study with Pembrolizumab in Patients with BRAF Mutant Negative Metastatic Melanoma
نویسندگان
چکیده
منابع مشابه
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.
PURPOSE Certain clinicopathologic features correlate with BRAF mutation status in melanoma including younger age and primary subtype. This study sought to determine the BRAF mutation status by age-decade and whether BRAF-mutant genotypes correlated with clinicopathologic features and outcome in patients with metastatic melanoma. METHODS A prospectively assembled cohort of Australian patients ...
متن کاملHuman Cancer Biology Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
Purpose:Certain clinicopathologic features correlate with BRAFmutation status inmelanoma including younger age and primary subtype. This study sought to determine the BRAFmutation status by age-decade and whether BRAF-mutant genotypes correlated with clinicopathologic features and outcome in patients with metastatic melanoma. Methods: A prospectively assembled cohort of Australian patients were...
متن کاملAssociation of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.
IMPORTANCE Vitiligo is an autoimmune skin disorder that reacts against melanocytes. The association of vitiligo with tumor response in patients with melanoma who undergo immunotherapy has been reported but is still controversial. OBJECTIVE To prospectively evaluate the appearance of vitiligo in patients receiving pembrolizumab, a monoclonal antibody directed against the programmed death cell ...
متن کاملTumoral Melanosis Associated with Pembrolizumab-Treated Metastatic Melanoma
Tumoral melanosis is a form of completely regressed melanoma that usually presents as darkly pigmented lesions suspicious for malignant melanoma. Histology reveals dense dermal and subcutaneous infiltration of melanophages. Pembrolizumab is an antibody directed against programmed death receptor-1 (PD1) and is frontline treatment for advanced melanoma. An 81-year-old man with metastatic melanoma...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Acta Facultatis Medicae Naissensis
سال: 2018
ISSN: 2217-2521
DOI: 10.2478/afmnai-2018-0028